We also plan to declare our first oral small molecule amylin development candidate later this quarter. We look forward to 2025 as a pivotal year for Structure.” Recent and Upcoming Milestones ...

UB neuroscientists have identified the binding site of low-dose ketamine, providing critical insight into how the medication alleviates symptoms of major depression in as little as a few hours.